Skip to content

Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance

FIT Versus Colonoscopy for Post-polypectomy Surveillance

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06983639
Enrollment
4000
Registered
2025-05-21
Start date
2026-01-09
Completion date
2050-01-01
Last updated
2026-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Neoplasms

Keywords

surveillance, polyp

Brief summary

From observational studies, it is know that the risk of developing colorectal cancer after polyp removal is lower if the patients adheres to surveillance recommendations. However, colonoscopy is burdensome for patients and colonoscopy availability is limited in many parts of the world. In addition, more than half of surveillance colonoscopies are without any findings. The trial investigates whether surveillance using fecal testing for blod is as good as colonoscopy after removal of colorectal polyps.

Detailed description

Colorectal cancer is the third most common cancer in the world and develops from benign colorectal polyps. Colonoscopy with polyp removal reduces colorectal cancer incidence and mortality. Patients who have had polyps removed are at increased risk for metachronous polyps and subsequent cancer and are referred to colonoscopic surveillance at regular intervals, the first one usually scheduled three years after polypectomy. Today, these comprise 15-25% of all colonoscopies, but in \>85%, no high-risk pathology is found. Thus, post-polypectomy surveillance consumes major resources without benefit to the patients, and these resources are much needed for colonoscopies due to other indications in an aging population. Additionally, colonoscopy requires burdensome bowel-cleansing, discomfort during the examination, absenteeism from work and sometimes need for an escort. Severe complications like bleeding and perforation may occur. Overdiagnosis and overtreatment of benign lesions occur in a large proportion of examinations as most polyps will never develop into colorectal cancer, even if left untreated. Sensitive fecal occult blood tests (FIT) have been developed that may detect colorectal cancer with the same sensitivity as colonoscopy. The test is cheap, is easily distributed by mail and may be performed at home. If the test detects blood, colonoscopy is indicated. FIT has been used in colorectal screening program for years, but has not yet been thoroughly investigated for post-polypectomy surveillance purposes. The trial is a pragmatic non-inferiority randomized trial in which patients who are eligible for 3-year colonoscopic surveillance are offered either colonoscopy (standard care) or FIT followed by a colonoscopy in case of a positive test result (Figure 1). FIT may decrease colonoscopy surveillance demand by \> 50%, which equals a cost saving of almost 30,000,000 Norwegian kroner annually. By proposing FIT for post-polypectomy surveillance, the trial introduce decentralized and personalized medical follow-up of these patients, and at the same time reduce work-absenteeism, patient discomfort, risk of complications and importantly: overdiagnosis and overtreatment of benign colorectal lesions.

Interventions

DIAGNOSTIC_TESTFecal occult blood testing

Fecal testing for blood as surveillance efter polyp removal

DIAGNOSTIC_TESTColonoscopy

Colonoscopy after polyp removal according to guidelines

Sponsors

Sykehuset Ostfold
CollaboratorOTHER
University Hospital, Akershus
CollaboratorOTHER
Vestre Viken Hospital Trust
CollaboratorOTHER
Sykehuset Telemark Hospital Trust
CollaboratorUNKNOWN
Helse Møre og Romsdal HF
CollaboratorOTHER_GOV
St. Olavs Hospital
CollaboratorOTHER
University Hospital of Northern Norway, Tromsø, Norway
CollaboratorUNKNOWN
Sykehuset i Vestfold HF
CollaboratorOTHER
Helse Stavanger HF
CollaboratorOTHER_GOV
Turku University Hospital
CollaboratorOTHER_GOV
Helsinki University Central Hospital
CollaboratorOTHER
Randers Regional Hospital
CollaboratorOTHER
Viborg Regional Hospital
CollaboratorOTHER
Gødstrup Hospital
CollaboratorOTHER
Horsens Hospital
CollaboratorOTHER
Sorlandet Hospital HF
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* High-quality baseline colonoscopy with adequat cleansing and cecal intubation * Remocval of at least one advanced adenoma * Clean colon (all polyps removed) * Signed informed consent

Exclusion criteria

* Colorectal cancer * History of surgical colon resection for any reason * Genetic cancer syndrome (adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome) * ≥ 10 adenomas at baseline colonoscopy (cumulative) * History of advanced serrated lesion, defined as SSL≥ 10mm or with dysplasia * Inflammatory bowel disease * On-going palliative care for any reason

Design outcomes

Primary

MeasureTime frame
Colorectal cancer incidence12 years from randomization

Secondary

MeasureTime frameDescription
Advanced neoplasia incidence3 years from randomizationFindings of colorectal cancer and high-risk polyps
Findings at colonoscopy12 years from randomizationPathology detected during colonoscopy in both arms
Colonoscopy utilization12 years after randomizationNumber of colonoscopies performed
Adherence12 years from randomizationAdherence with colonoscopy and FIT surveillance recommendations. Proportion of participants in each arm who are invited for colonoscopy or FIT surveillance and who actually adheres submit the FIT/undergo colonoscopy.
Colorctal cancer mortality12 years from randomization
Adverse events30 days after colonoscopyAdverse events after colonoscopy
Carbon footprint12 years after randomizationThe carbon footprint in each arm will be calculated and compared. Carbon footprint is the total carbon emission from manufacturing, shipping, use, prosessing, litter-handling etc
FIT accuracy3 years after randomizationSensitivity, specificity, postive predictive value and negative predicitive value for colorectal cancer and advanced neoplasia at different FIT-thresholds
Cost-effectiveness12 years from randomizationTotal cost for FIT-surveillance and colonoscopy surveillance will be calculated and compared, including reimbursement (FIT, colonoscopy, pathology assessment), payment from patients, travel, absenteism from work, cost of complications etc.

Countries

Norway

Contacts

Primary ContactØyvind Holme
oyvind.holme@sshf.no004738073000
Backup ContactMichael Bretthauer
michael.bretthauer@medisin.uio.no004790132480

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026